专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110123575A1 MODIFIED RELEASE NIACIN FORMULATIONS 审中-公开
标题翻译：改良释放NIACIN制剂
公开(公告)号：US20110123575A1
公开(公告)日：2011-05-26
申请号：US12995718
申请日：2009-06-02
申请人： Rajesh Vooturi , Dhanajay Singare , Shantanu Yeshwant Damle , Pradeep Jairao Karatgi , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Ish Kumar Khanna , Raviraj Sukumar Pillai
发明人： Rajesh Vooturi , Dhanajay Singare , Shantanu Yeshwant Damle , Pradeep Jairao Karatgi , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Ish Kumar Khanna , Raviraj Sukumar Pillai
IPC分类号： A61K9/00 , A61K31/4406 , A61P3/06 , A61P9/10
CPC分类号： A61K31/455 , A61K9/5031 , A61K9/5047 , A61K9/5073
摘要： Modified release pharmaceutical formulations comprising niacin in a non-swellable core, and processes for preparation of the formulations.
摘要翻译：包含非可溶胀核心中的烟酸的改性释放药物制剂以及制剂的制备方法。

2. 发明申请

US20120064161A1 MODIFIED RELEASE NIACIN PHARMACEUTICAL FORMULATIONS 审中-公开
标题翻译：改良释放NIACIN药物制剂
公开(公告)号：US20120064161A1
公开(公告)日：2012-03-15
申请号：US13299591
申请日：2011-11-18
申请人： Rajesh Vooturi , Dhananjay Singare , Shantanu Yeshwant Damle , Pradeep Jairao Karatgi , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Ish Kumar Khanna , Raviraj Sukumar Pillai , Sivaram Pillarisetti
发明人： Rajesh Vooturi , Dhananjay Singare , Shantanu Yeshwant Damle , Pradeep Jairao Karatgi , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Ish Kumar Khanna , Raviraj Sukumar Pillai , Sivaram Pillarisetti
IPC分类号： A61K9/28 , A61P9/12 , A61K9/32 , A61K31/455 , A61K9/36
CPC分类号： A61K31/455 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical formulations comprising niacin in a matrix comprising a hydrophobic polymer that modifies release of niacin.
摘要翻译：包含烟酸在包含改性烟酸释放的疏水性聚合物的基质中的药物制剂。

3. 发明申请

US20110086074A1 COMBINATIONS OF NIACIN AND AN OXICAM 审中-公开
标题翻译： NIACIN和OXICAM的组合
公开(公告)号：US20110086074A1
公开(公告)日：2011-04-14
申请号：US12995711
申请日：2009-06-02
申请人： Pradeep Jairao Karatgi , Thilek Kumar Muniyappan , Shantanu Yeshwant Damle , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Raviraj Sukumar Pillai , Ish Kumar Khanna
发明人： Pradeep Jairao Karatgi , Thilek Kumar Muniyappan , Shantanu Yeshwant Damle , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Raviraj Sukumar Pillai , Ish Kumar Khanna
IPC分类号： A61K31/549 , A61K9/00 , A61P29/00 , A61P3/06 , A61P3/10
CPC分类号： A61K31/455 , A61K9/2081 , A61K9/209 , A61K9/2886 , A61K9/5026 , A61K9/5073 , A61K9/5084 , A61K31/54 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical formulations comprising a combination of niacin and an oxicam NSAID, for oral administration, and methods of preparing the formulations.
摘要翻译：包含烟酸和奥昔康NSAID的组合用于口服给药的药物制剂和制备该制剂的方法。

4. 发明授权

US06900232B2 Cycloalkyl alkanoic acids as integrin receptor antagonists 失效
标题翻译：环烷基链烷酸作为整联蛋白受体拮抗剂
公开(公告)号：US06900232B2
公开(公告)日：2005-05-31
申请号：US09882186
申请日：2001-06-15
申请人： Ish Kumar Khanna , Michael Clare , Alan F. Gasiecki , Thomas Rogers , Barbara Chen , Mark Russell , Hwang-Fun Lu
发明人： Ish Kumar Khanna , Michael Clare , Alan F. Gasiecki , Thomas Rogers , Barbara Chen , Mark Russell , Hwang-Fun Lu
IPC分类号： A61K31/4168 , A61K31/4375 , A61K31/44 , A61K31/4402 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/5383 , A61P3/14 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/10 , A61P21/00 , A61P27/02 , A61P35/00 , A61P35/04 , C07D213/74 , C07D231/38 , C07D233/88 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D498/04 , C07D213/72
CPC分类号： C07D213/74 , C07D231/38 , C07D233/88 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要： The present invention relates to a class of compounds represented by the Formula I Wherein A1 is a pyridinyl of the formula optionally substituted by one or more Rk selected from the group consisting of hydroxy, alkyl, alkoxy, alkoxyalkyl, thioalkyl, haloalkyl, cyano, amino alkylamino, halogen, acylamino, sulfonamide and —COR; and R is hydroxy, alkoxy, alkyl or amino; and pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.
摘要翻译：本发明涉及由式I表示的一类化合物，其中A 1是下式的吡啶基，其任选被一个或多个选自下组的R 0选自羟基，烷基，烷氧基，烷氧基烷基，硫代烷基，卤代烷基，氰基，氨基烷基氨基，卤素，酰氨基，磺酰胺和-COR; 且R为羟基，烷氧基，烷基或氨基; 和其药学上可接受的盐，包含式I化合物的药物组合物，以及选择性抑制或拮抗α3β3和/或α / 5> 5＆lt; 5＆gt;整联蛋白。

5. 发明授权

US06531494B1 Gem-substituted &agr;v&bgr;3 antagonists 失效
标题翻译：宝石取代的alphavbeta3拮抗剂
公开(公告)号：US06531494B1
公开(公告)日：2003-03-11
申请号：US09942214
申请日：2001-08-29
申请人： Ish Kumar Khanna , Yi Yu , Balekudru Devadas , Hwang-Fun Lu , Nizal S Chandrakumar , Renee M. Huff , Bipinchandra N. Desai , Srinivasan Raj Nagarajan , Alan F. Gasiecki , Thomas D. Penning , Mark A. Russell , Mark L. Boys , Lori A. Schretzman , Barbara B. Chen , Thomas Rogers , John Adam Wendt , Albert Khilevich , Yaping Wang
发明人： Ish Kumar Khanna , Yi Yu , Balekudru Devadas , Hwang-Fun Lu , Nizal S Chandrakumar , Renee M. Huff , Bipinchandra N. Desai , Srinivasan Raj Nagarajan , Alan F. Gasiecki , Thomas D. Penning , Mark A. Russell , Mark L. Boys , Lori A. Schretzman , Barbara B. Chen , Thomas Rogers , John Adam Wendt , Albert Khilevich , Yaping Wang
IPC分类号： A61K3144
CPC分类号： C07D213/74 , C07D213/73 , C07D401/12 , C07D471/04
摘要： The present invention relates to a class of compounds represented by the Formula I. or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr;V&bgr;3 and/or the &agr;V&bgr;5 integrin.
摘要翻译：本发明涉及一类由式I表示的化合物或其药学上可接受的盐，包含式I化合物的药物组合物，以及选择性抑制或拮抗αVβ3和/或αVβ5整联蛋白的方法。

6. 发明申请

US20130303525A1 KAPPA OPIOID RECEPTOR AGONISTS 有权
公开(公告)号：US20130303525A1
公开(公告)日：2013-11-14
申请号：US13811020
申请日：2011-07-19
申请人： Pradip Kumar Sasmal , Vamsee Krishna Chintakunta , Vijay Potluri , Ish Kumar Khanna , Ashok Tehim , Mahaboobi Jaleel , Thomas Hogberg , Oystein Rist , Lisbeth Elster , Thomas Michael Frimurer , Lars-Ole Gerlach
发明人： Pradip Kumar Sasmal , Vamsee Krishna Chintakunta , Vijay Potluri , Ish Kumar Khanna , Ashok Tehim , Mahaboobi Jaleel , Thomas Hogberg , Oystein Rist , Lisbeth Elster , Thomas Michael Frimurer , Lars-Ole Gerlach
IPC分类号： C07D419/12 , C07D401/12 , C07D413/14 , C07D403/12 , C07D207/09 , C07D417/12 , C07D413/12
CPC分类号： C07D419/12 , C07D207/09 , C07D207/12 , C07D209/34 , C07D213/76 , C07D215/12 , C07D215/227 , C07D231/56 , C07D249/18 , C07D261/20 , C07D263/56 , C07D263/58 , C07D275/06 , C07D277/30 , C07D279/02 , C07D295/13 , C07D401/12 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
摘要翻译：本发明涉及一系列具有通式（I）的取代的化合物，包括其立体异构体和/或其药学上可接受的盐。（I）其中A，m，R 1，R 2，R 3，R 4如本文所定义。本发明还涉及制备这些化合物包括中间体的方法。本发明的化合物在κ（κ）阿片样物质受体（KOR）位点是有效的。因此，本发明的化合物可用作药物，特别是用于治疗和/或预防各种中枢神经系统疾病（CNS），包括但不限于急性和慢性疼痛以及相关疾病，特别是周边功能在CNS。

7. 发明授权

US07989463B2 Biccyclic compounds as GATA modulators 失效
标题翻译：双环化合物作为GATA调节剂
公开(公告)号：US07989463B2
公开(公告)日：2011-08-02
申请号：US12553694
申请日：2009-09-03
申请人： Dibyendu De , Ish Kumar Khanna , Sivaram Pillarisetti
发明人： Dibyendu De , Ish Kumar Khanna , Sivaram Pillarisetti
IPC分类号： A61K31/517
CPC分类号： C07D239/70 , C07D401/04 , C07D403/04 , C07D413/04
摘要： Novel bicyclic compounds of the formula (I), stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided: wherein R1, R2, m, and n are defined herein.
摘要翻译：提供式（I）的新型双环化合物，新型双环化合物的立体异构体和/或药学上可接受的盐，和/或新型双环化合物的立体异构体的药学上可接受的盐。另外，提供了形成新型双环化合物的新型双环化合物，立体异构体和/或药学上可接受的盐的方法，和/或新型双环化合物的立体异构体的药学上可接受的盐：其中R1，R2，m和n为本文定义。

8. 发明授权

US06933304B2 Heteroarylalkanoic acids as integrin receptor antagonists 失效
标题翻译：杂芳基链烷酸作为整联蛋白受体拮抗剂
公开(公告)号：US06933304B2
公开(公告)日：2005-08-23
申请号：US09881913
申请日：2001-06-15
申请人： Srinivasan Raj Nagarajan , Ish Kumar Khanna , Michael B. Tollefson , Scott B. Mohler , Barbara Chen , Mark Russell , Balekudru Devadas , Thomas D. Penning , Lori A. Schretzman , Dale P. Spangler , Mark Laurence Boys , Nizal Samuel Chandrakumar , Hung-Fun Lu
发明人： Srinivasan Raj Nagarajan , Ish Kumar Khanna , Michael B. Tollefson , Scott B. Mohler , Barbara Chen , Mark Russell , Balekudru Devadas , Thomas D. Penning , Lori A. Schretzman , Dale P. Spangler , Mark Laurence Boys , Nizal Samuel Chandrakumar , Hung-Fun Lu
IPC分类号： A61K31/4245 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/5383 , A61P3/14 , A61P9/00 , A61P9/08 , A61P9/10 , A61P19/02 , A61P19/10 , A61P21/00 , A61P27/02 , A61P35/00 , A61P43/00 , C07D213/74 , C07D231/38 , C07D233/60 , C07D233/88 , C07D405/12 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D498/04
CPC分类号： C07D213/74 , C07D231/38 , C07D233/88 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要： The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively antagonizing the αVβ3 and/or the αVβ5 integrin without significantly antagonizing the IIb/IIIa or αVβ6 integrin.
摘要翻译：本发明涉及一类由式I表示的化合物或其药学上可接受的盐，包含式I化合物的药物组合物和选择性拮抗α-β3 和/或α5AT55整联蛋白，而不显着拮抗IIb / IIIa或α5β6 / SUB>整合素。

9. 发明授权

US06833366B1 Dihydrostilbene alkanoic acid derivatives 失效
标题翻译：二氢芪链烷酸衍生物
公开(公告)号：US06833366B1
公开(公告)日：2004-12-21
申请号：US10657932
申请日：2003-09-09
申请人： Thomas Rogers , Michael Clare , Hwang-Fun Lu , Mark Russell , James W. Malecha , Ish Kumar Khanna , Thomas Penning , Srinivasan Raj Nagarajan
发明人： Thomas Rogers , Michael Clare , Hwang-Fun Lu , Mark Russell , James W. Malecha , Ish Kumar Khanna , Thomas Penning , Srinivasan Raj Nagarajan
IPC分类号： A61K3133
CPC分类号： C07D213/74 , C07D239/14 , C07D401/12
摘要： The present invention relates to a class of compounds represented by the Formula 1. or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula 1, and methods of selectively inhibiting or antagonizing the &agr;v&bgr;3 and/or the &agr;v&bgr;5 integrin.
摘要翻译：本发明涉及一类由式1表示的化合物或其药学上可接受的盐，包含式1的化合物的药物组合物，以及选择性抑制或拮抗阿尔法博三唑和/或阿尔法肽5整联蛋白的方法。

10. 发明授权

US5861403A Purinylalkyl benzamide derivatives 失效
标题翻译：丙基烷基苯甲酰胺衍生物
公开(公告)号：US5861403A
公开(公告)日：1999-01-19
申请号：US725307
申请日：1996-10-02
申请人： Ish Kumar Khanna , Richard Mathias Weier
发明人： Ish Kumar Khanna , Richard Mathias Weier
IPC分类号： C07D473/00 , A61K31/52 , C07D473/30 , C07D473/40
CPC分类号： C07D473/00
摘要： The present invention relates to compounds of the formula ##STR1## wherein HET is ##STR2## m is an integer from 1 to 4; R.sup.1 and R.sup.2 are independently selected from the group consisting of linear or branched alkyl of 1 to 6 carbon atoms; and cycloalkyl or cycloalkylalkyl having 3 to 7 ring carbon atoms, the ring carbon atoms optionally substituted with one or more alkyl groups having 1 to about 4 carbon atoms each;X is a substituent selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkylthio, and alkylthioalkyl, wherein each of said alkyl moieties has from 1 to about 6 carbon atoms; andY and Z are independently selected from the group consisting of hydrogen, alkoxy of about 1 to 6 carbon atoms and halogen;and pharmaceutical compositions containing a therapeutically effective amount of the compounds in combination with a pharmaceutically acceptable carrier and a method for treating diseases mediated by platelet activating factor.
摘要翻译：本发明涉及下式的化合物，其中HET是（i）图像（ii）和（iii）m是1至4的整数; R 1和R 2独立地选自具有1至6个碳原子的直链或支链烷基; 和环碳原子数为3〜7的环烷基或环烷基烷基，环碳原子任选被一个或多个具有1至约4个碳原子的烷基取代; X是选自氢，卤素，烷基，烷氧基，烷氧基烷基，氨基烷基，烷基氨基烷基，二烷基氨基烷基，烷硫基和烷硫基烷基的取代基，其中每个所述烷基部分具有1至约6个碳原子; Y和Z独立地选自氢，约1至6个碳原子的烷氧基和卤素; 以及含有治疗有效量的化合物与药学上可接受的载体组合的药物组合物和用于治疗由血小板活化因子介导的疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式